Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 6/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.42 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17409929 | 0.81 | KIF11 (0.43) | KDM4EGPR3HTR3EHTR3BHTR3A | |
| SCHEMBL29997743 | 0.78 | GPR3 (0.48) | KDM4EGPR3BCHEACHEADORA3 | |
| SCHEMBL21187770 | 0.76 | MAPT (0.54) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8218623 | 0.75 | ACHE (0.43) | BCHEACHECHRM1GRIN1GRIN2A | |
| SCHEMBL17484147 | 0.75 | HTR2C (0.44) | KDM4EGPR3 | |
| SCHEMBL9097938 | 0.75 | ACHE (0.48) | KDM4EACHETSHRALDH1A1HSD17B10 | |
| Phenanthridine SCHEMBL27966445 | 0.75 | KDM4E (0.56) | KDM4EGPR3HTR3EHTR3BHTR3A | |
| SCHEMBL17413634 | 0.75 | KDM4E (0.43) | KDM4EGPR3HTR3EHTR3BHTR3A | |
| SCHEMBL4681814 | 0.75 | MAPT (0.39) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17413693 | 0.75 | KDM4E (0.43) | KDM4EGPR3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53068780-A | — | — | None | — | — | JP | disclosed |
| US-11616203-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190319198-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION | 2019-10-17 | — | — | US | disclosed |
| US-20140088066-A1 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BLEND THERAPEUTICS (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014043243-A2 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BLEND THERAPEUTICS (US) | 2014-03-20 | — | — | WO | disclosed |
| US-5442065-A | Antitumor agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0594624-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0594624-A4 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE. | SCRIPPS CLINIC RES (US) | 1994-02-21 | — | — | EP | disclosed |
| WO-1992002522-A1 | DYNEMICIN ANALOGS: SYNTHESES, METHODS OF PREPARATION AND USE | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-02-20 | — | — | WO | disclosed |
| JP-S5368780-A | PREPARATION OF 7,8,9,10-TETRAHYDROPHENANTHRIDINE-3-ACETIC ACIDS | TEIJIN LTD | 1978-06-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11616203-B2 | Organic electroluminescent materials and devices | ICOSLG, APOL1, OXA1L | KDM4E 3691/4885GPR3 2321/4885HTR3E 4069/4885 |
| US-20140088066-A1 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | APEX1, DPYD, VHL | KDM4E 2370/4885GPR3 3910/4885HTR3E 3783/4885 |
| US-20190319198-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, APOL1, OXA1L | KDM4E 3691/4885GPR3 2321/4885HTR3E 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.